Search results
4 days ago · DIFICID® (fidaxomicin) is a macrolide antibacterial drug indicated in adult and pediatric patients 6 months of age and older for treatment of Clostridioides difficile-associated diarrhea (CDAD).
Jun 27, 2024 · Among patients with Clostridioides difficile infection (CDI), fidaxomicin is superior to vancomycin as first-line treatment, according to study results published in The Journal of Infectious Diseases.
Jun 15, 2024 · In 2022, the FDA approved Rebyota, the first fecal microbiota product, and in 2023, Vowst, the first fecal microbiota product taken orally. Rebyota and Vowst are approved for the prevention of the recurrence of C. diff infections in adults who have completed antibiotic treatment for recurrent C. diff infections.
Jun 29, 2024 · Clostridioides dificile (CD) is a Gram-positive, anaerobic bacterium that is one of the most common causes of infective diarrhoea worldwide [1]. Among hospitalized patients, Clostridioides dificile infection (CDI) leads to increased morbidity, mortality, and extended hospital stays.
5 days ago · Consequently, fidaxomicin offers a significant advantage over broad-spectrum antibiotics, which often lead to secondary infections and other complications due to their non-specific action. Administering fidaxomicin follows a straightforward regimen, making it convenient for patients and healthcare providers.
Jun 15, 2024 · Most patients with C. diff can be prescribed a course of Flagyl (metronidazole), vancomycin, or Dificid (fidaxomicin). The treatment may need to be repeated if the infection doesn't get better or comes back.
4 days ago · The fidaxomicin study provided the first evidence that relapse of disease may be able to be reduced. New phase 2 study findings on the use of a monoclonal antibody were reported at Digestive Disease Week 2009. [10]
